Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabina Signoretti

Showing results (121-130 of 257) with videos related to

Pageof 26
Sort By:
Journal for Immunotherapy of Cancer|August 16, 2023
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastasesDavid A Schoenfeld, Myrto Moutafi, Sandra Martinez, et al.
Cell|July 2, 2016
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses CysteineKimberly J Briggs, Peppi Koivunen, Shugeng Cao, et al.
Clinical Genitourinary Cancer|April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell CarcinomaKathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.
Journal for Immunotherapy of Cancer|December 22, 2022
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinomaBrian I Rini, Sabina Signoretti, Toni K Choueiri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Tissue-based research in kidney cancer: current challenges and future directionsSabina Signoretti, Gennady Bratslavsky, Frederick M Waldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal CancerLiang Zhang, Xiaoen Wang, Andrea J Bullock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell CarcinomaThomas Denize, Yue Hou, Jean-Christophe Pignon, et al.
Science Translational Medicine|January 21, 2021
ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinomaPrateek Khanna, Hong Jie Soh, Chun-Hau Chen, et al.
Cancer Cell|November 16, 2010
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesisBoyi Gan, Carol Lim, Gerald Chu, et al.
The Lancet. Oncology|October 2, 2025
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer ConsortiumJames P Blackmur, J C Koen van der Mijn, Anne Y Warren, et al.
Pageof 26

Showing results (121-130 of 257) with videos related to

Sort By:
Pageof 26
Journal for Immunotherapy of Cancer|August 16, 2023
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastasesDavid A Schoenfeld, Myrto Moutafi, Sandra Martinez, et al.
Cell|July 2, 2016
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses CysteineKimberly J Briggs, Peppi Koivunen, Shugeng Cao, et al.
Clinical Genitourinary Cancer|April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell CarcinomaKathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.
Journal for Immunotherapy of Cancer|December 22, 2022
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinomaBrian I Rini, Sabina Signoretti, Toni K Choueiri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Tissue-based research in kidney cancer: current challenges and future directionsSabina Signoretti, Gennady Bratslavsky, Frederick M Waldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal CancerLiang Zhang, Xiaoen Wang, Andrea J Bullock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell CarcinomaThomas Denize, Yue Hou, Jean-Christophe Pignon, et al.
Science Translational Medicine|January 21, 2021
ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinomaPrateek Khanna, Hong Jie Soh, Chun-Hau Chen, et al.
Cancer Cell|November 16, 2010
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesisBoyi Gan, Carol Lim, Gerald Chu, et al.
The Lancet. Oncology|October 2, 2025
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer ConsortiumJames P Blackmur, J C Koen van der Mijn, Anne Y Warren, et al.
Pageof 26